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Abstract
Androgen deprivation therapy (ADT) is the standard care for prostate cancer (PCa) patients who fail surgery or radiotherapy.
While initially effective, the cancer almost always recurs as a more aggressive castration resistant prostate cancer (CRPC).
Previous studies have demonstrated that chromatin modifying enzymes can play a critical role in the conversion to CRPC.
However, only a handful of these potential pharmacological targets have been tested. Therefore, in this study, we conducted
a focused shRNA screen of chromatin modifying enzymes previously shown to be involved in cellular differentiation. We
found that altering the balance between histone methylation and demethylation impacted growth and proliferation. Of all
genes tested, KDM3B, a histone H3K9 demethylase, was found to have the most antiproliferative effect. These results were
phenocopied with a KDM3B CRISPR/Cas9 knockout. When tested in several PCa cell lines, the decrease in proliferation
was remarkably specific to androgen-independent cells. Genetic rescue experiments showed that only the enzymatically
active KDM3B could recover the phenotype. Surprisingly, despite the decreased proliferation of androgen-independent cell
no alterations in the cell cycle distribution were observed following KDM3B knockdown. Whole transcriptome analyses
revealed changes in the gene expression profile following loss of KDM3B, including downregulation of metabolic enzymes
such as ARG2 and RDH11. Metabolomic analysis of KDM3B knockout showed a decrease in several critical amino acids.
Overall, our work reveals, for the first time, the specificity and the dependence of KDM3B in CRPC proliferation.
Introduction
Androgen receptor (AR) signaling is critical at all stages of
prostate cancer (PCa) progression. Given this essential role,
recurrent, advanced, or metastatic PCa is commonly treated
with androgen deprivation therapy (ADT) [1]. Typically,
this treatment is initially successful and causes a decrease in
both serum prostate specific antigen (PSA) and tumor
volume [1, 2]. However, ADT is not curative and in almost
all patients the cancer develops resistances and recurs as a
more aggressive castration resistant prostate cancer (CRPC)
[2, 3]. While there is almost no circulating androgen in
these patients, extensive clinical evidence has demonstrated
that the AR still remains active in CRPC [4]. Several dif-
ferent mechanisms have been demonstrated to drive AR-
recurrence including: AR amplifications and over-
expression, intratumoral testosterone synthesis, AR muta-
tions, AR splice variants, aberrant regulation of the
coactivators of AR, and others [4–9]. There is also
increasing evidence that epigenetic modifications play a
critical role in the development of CRPC. Specifically,
alterations to the epigenetic state can provide a transcrip-
tional landscape that allows the differentiated androgen-
dependent epithelial cells to gain androgen-independent
characteristics [10, 11]. It is only through the cellular stress
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of ADT that the cancer can overcome differentiation bar-
riers through epigenetic alterations and adopt to castrate
conditions [12]. Given this critical role, these epigenetic
modifying proteins could offer promising pharmacological
targets to treat CRPC.
Numerous lysine demethylases have also been shown to
impact the growth and proliferation of PCa [13]. Metzger
et al. demonstrated that KDM1A overexpression associates
with poor clinical outcome in PCa [11]. KDM1A, an
H3K4me1/2 demethylase, is proposed to change the sub-
strate specificity of KDM1A toward H3K9me1/2 upon
interaction with AR [11]. KDM3A interacts with AR
through an LxxLL motif and regulates AR-target gene
expression [14]. Demonstrating its importance in AR sig-
naling, loss of KDM3A resulted in smaller testis size and
decreased sperm count in mice [15]. While not linked to
PCa, KDM3B is essential to spermatogenesis in vivo [16].
Similarly, KDM4A, KDM4B, and KDM5B can impact AR
activity in PCa cells [17–19]. KDM4A, for example,
interact with AR and overexpression of KDM4A leads to
AR-mediated PSA transcription [17]. Clinical data suggests
that KDM4A positively correlates with the aggressiveness
of PCa tumors [20]. KDM4B can regulate AR recruitment
and enhance transcriptional activity [18]. PHF8 (KDM7B)
act as a coactivator of AR that is activated in hypoxic
tumors [21, 22].
Much of this research has focused on the relationship
between AR signaling and chromatin modifiers. Only a
small number of epigenetic modifying enzymes have been
studied in an androgen-independent context despite the
extensive transcriptional alternations that occur during the
development of ADT resistance. In stem cell biology,
numerous epigenetic modifying enzymes have been iden-
tified that are required for cellular dedifferentiation to
pluripotency [23, 24]. As both iPSC and CRPC progression
involve cellular dedifferentiation, the genes involved in this
process could potentially be similar. Therefore, in this work
we systematically screened a focused shRNA library of
chromatin modifying enzymes previously linked to stem
cell differentiation to characterize their role in androgen-
independent growth [23]. Our screen showed that
perturbation in the histone methylation/demethylation
homeostasis lead to alteration in the proliferative capacity of
the cells. Among the hits that showed inhibitory effect,
KDM3B was particularly interesting as it has not been
studied in CRPC. We validated the specificity of the phe-
notype in CRPC cells and demonstrated that enzymatic
activity of KDM3B is required. Knockdown of KDM3B led
to changes in global gene expression associated with
metabolic changes. To address the mechanism, we investi-
gated metabolic changes under loss of KDM3B conditions.
Overall, this work represents the first study to demonstrate
the importance of KDM3B in CRPC.
Results
Knockdown of various chromatin modifiers alter
proliferation in LNCaP-abl cells
To understand how hormone-sensitive PCa transition to
CRPC, we conducted a focused shRNA screen of chromatin
modifiers that had previously been shown to act as facil-
itators and barriers of somatic cell reprograming [23]. This
includes chromatin modifying enzymes (methyltransferases,
histone variant, methyl readers, and demethylases), tran-
scriptional regulators, and E3-ubiquitin ligases (n= 119,
targeting 47 different genes, Supplementary Table S1). This
screen was done in LNCaP-abl cells, a model of androgen-
independent CRPC derived from the androgen-sensitive
LNCaP (Fig. 1a) [25] . From this screen, 43 individual
shRNAs increased and 38 shRNAs decreased proliferation
of LNCaP-abl. Approximately half of the hits with “pro-
proliferative” effect (9/17 enzymes, average normalized
proliferation of all shRNAs per target) were histone
methyltransferases such as EED [26], and DNA methyl-
transferase 1 (DNMT1), both had been shown to correlate
with PCa aggressiveness [26]. In contrast, 12 genes had an
inhibitory effect on the growth of LNCaP-abl, including
KDM1A and EZH2, which had previously demonstrated to
be essential for CRPC growth [10, 11]. We also observed a
cluster of JmjC-KDMs including KDM4A, KDM4B, and
KDM5A that have been implicated for their role in PCa
[27]. Overall, we found that most histone methylation
associated enzymes and demethylases led to opposing
effects, highlighting that histone methylation status is linked
to cellular proliferation in CRPC.
From our screen KDM3B knockdown was found to have
the most significant antiproliferative effect in our CRPC
model (Fig. 1a). To validate the screen results, we then
retested the impact of KDM3B knockdown in both the
parental androgen-dependent LNCaP and androgen-
independent LNCaP-abl cells (Fig. 1b, Supplementary
Table S1). Knockdown of KDM3B decreased the pro-
liferation of LNCaP-abl cells but did not affect LNCaP
cells. Efficient knockdown of KDM3B at the mRNA and
protein levels was observed in both cell lines (Fig. 1c).
Given the critical role of AR in LNCaP-abl, we next tested
AR expression upon KDM3B knockdown. No effect on AR
protein expression was observed (Supplementary Fig. S1a),
suggesting that the observed phenotype was not due to
altered AR expression. Supporting this, when we performed
KDM3B knockdown in both castrate and androgen sup-
plemented media we did not observe any change in the
proliferation (Supplementary Fig. S1b). These results show
that this lysine demethylase does not function through the
AR signaling pathway. To confirm our loss-of-function
results we generated CRISPR/Cas9 mediated KDM3B
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knockouts. Cells treated with Cas9 and three individual
KDM3B or AR [28] targeting gRNAs showed targeted
knockout of either AR or KDM3B (Fig. 2a). Consistent
with our earlier results, knockout of KDM3B decreased the
proliferation of LNCaP-abl but not LNCaP cells (Fig. 2b).
To confirm that this phenotype was not specific to the assay
used, we monitored the cell proliferation of LNCaP-abl and
LNCaP using real-time cell analysis (RTCA). In this, the
Fig. 1 Knockdown of various chromatin modifying enzymes
impacted proliferation of androgen-independent LNCaP-abl cells.
a Cells were transduced with shRNA library targeting different
enzymes. Following puromycin selection, cells were plated on a 96-
well plate in equal numbers and then assayed for proliferation by MTS
on day 7. Proliferation was normalized to a nontargeting shRNA
control (shFF). Red bars showing shRNAs targeting KDM3B (n= 3,
SEM). b LNCaP-abl and LNCaP WT cells were transduced with three
independent shKDM3B and assayed as previously described. (n= 3,
SEM, *p < 0.05, **p < 0.01, ***p < 0.001, statistically normalized to
shFF control). c Relative KDM3B mRNA levels (top) and protein
(bottom) following shRNA knockdown. RNA was normalized to ß-
actin by 2−ΔΔCt method (n= 3, SEM, *p < 0.05, **p < 0.01, ***p <
0.001). KDM3B protein expression levels are shown following treat-
ment with three independent shRNAs in LNCaP-abl and LNCaP
WT cells. ɑ-Tubulin was used as loading control.
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loss of KDM3B caused a significant decrease of LNCaP-abl
proliferation (Fig. 2c). Similar to earlier results, knockout of
KDM3B did not affect the growth of LNCaP. While one
gRNA targeting KDM3B actually caused increased pro-
liferation, this is likely an off-target effect as it was not
observed with the other gRNA or shRNA.
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Next, we investigated the effect of KDM3B knockdown
in a variety of prostate cell lines. In these experiments, we
used the most efficient shKDM3B (shKDM3B-1; #sh113).
Knockdown of KDM3B did not alter the proliferation of
RWPE-1 (immortalized prostatic epithelial), PC3 (AR
negative), 22Rv1 (AR expressing and constitutively active
splice variant), DU145 (AR negative), VCaP (AR expres-
sing and constitutively active splice variant), and LNCaP
[25, 29–35]. However, downregulation of KDM3B resulted
in decreased proliferation of the two androgen-independent
CRPC cells (LNCaP-abl and LNAI) (Fig. 2d). Knockdown
of KDM3B was validated in all cells by qRT-PCR (Sup-
plementary Fig. S2). To confirm these results, we tested the
effect of shKDM3B on proliferation with LNCaP, LNCaP-
abl, and LNAI cells by RTCA (Fig. 2e). Knockdown of
KDM3B resulted in decreased proliferation of LNCaP-abl
and LNAI, while LNCaP cells were less affected. Taken
together, these results establish KDM3B as an important
gene for the proliferation of AR-expressing androgen-
independent CRPC cells.
Loss of KDM3B causes decreased androgen-
independent growth and the effect is dependent on
KDM3B histone demethylation activity
To characterize the role of KDM3B on androgen-
independent growth in PCa, we conducted genetic rescue
experiments in shKDM3B expressing cells. There are three
reported isoforms of KDM3B (Fig. 3a). Isoform-1 (1761
AA) is proposed to be the canonical form with a Jumonji-C
(JmjC) domain, C2HC4 zinc-finger domain, serine-rich
domain, and a LxxLL motif [36, 37]. Isoform-2 is slightly
shorter with a truncated N-terminus [38], while Isoform-3
lacks the first 1000 amino acids and does not contain the
nuclear localization signal [38]. Isoform-2 is not commonly
expressed and therefore was not included in our analysis
[38–40]. In the KDM3B JmjC domain there are two histi-
dine residues (His1560 and His1689) that interact with Fe
(II) and are essential for demethylase activity [39]. In our
rescue experiment we tested isoform 1 (wild type), isoform
3 (iso3), an enzymatically inactive JmjC domain
(His1560Ala) and zinc-finger deleted (KDM3BΔZF)
KDM3B mutant (Fig. 3a). Each of these constructs had
similar mRNA and protein expression compared with wild-
type KDM3B (Supplementary Fig. S3). To demonstrate the
enzymatic activity of these KDM3B constructs, we con-
ducted immunofluorescence staining of H3K9me2 in tran-
siently transfected cells. While all constructs were
expressed, only the wild-type KDM3B was enzymatically
active and could efficiently demethylated the H3K9me2
mark (Fig. 3b). Having validated these overexpression
constructs, we then transfected them into LNCaP-abl cells
treated with KDM3B shRNA. Expression of these rescue
constructs did not affect the growth in cells treated with
control shRNA (shFF). However, the enzymatically active
KDM3B partially rescued the proliferation phenotype in the
shKDM3B treated cells, while GFP (negative control),
KDM3B-H1560A, iso3, and KDM3BΔZF overexpression
had no effect (Fig. 3c).
Next, we tested the effect of small molecule JmjC-
inhibitors targeting the catalytic activity of KDMs on cell
proliferation. We observed inhibition of the growth of
LNCaP-abl (IC50 0.14 µM) and LNCaP (IC50 ~1 µM) and a
weaker inhibition in normal prostate epithelial cells RWPE-
1 (IC50 ~20 µM) upon treatment with JIB-04, a pan-KDM
inhibitor, which can also inhibit KDM3 (Fig. 3d) [41, 42].
Interestingly, androgen-independent LNCaP-abl was more
sensitive than androgen-dependent LNCaP cells, in line
with our shRNA studies. When we tested the broad spec-
trum 2OG oxygenase inhibitors, IOX1 [43] and DMOG
(pro-drug of 2OG mimic N-oxalylglycine) [44], both PCa
cell lines were found to be as sensitive as prostate epithelial
RWPE-1 cells (Supplementary Fig. S4), suggesting KDM-
independent mechanisms are also likely associated with
these compounds. Overall, pan-KDM inhibition shows
antiproliferative effect in PCa, particularly in LNCaP-abl
CPRC cells.
Together with the RNAi data, our results suggest that the
CRPC cell proliferation is, in part, dependent on the cata-
lytic activity of KDM3B.
KDM3B does not alter cell cycle or AR signaling in
LNCaP-abl cells
Having demonstrated that KDM3B is important to
androgen-independent cell growth, we next investigated the
molecular mechanism. We first assayed the cell cycle dis-
tribution after KDM3B knockdown. Interestingly, we did
not observe any blockade at specific cell cycle stages (Fig.
4a, b, Supplementary Fig. S5). Although shKDM3B1
treatment exhibited slight alterations of S phase by PI
staining this was not reproducible, and we did not observe
the same phenotype with BrdU staining. Thus, KDM3B
knockdown appears to cause a decrease in the cell cycle rate
Fig. 2 Downregulation or loss of KDM3B decreases the pro-
liferation of androgen-independent cells. CRISPR/Cas9-mediated
KDM3B knockout phenocopied the decreased proliferation phe-
notype in LNCaP-abl cells. a Western blot of LNCaP-abl Cas9 and
LNCaP Cas9 cells transduced with targeted gRNA. The effect of
KDM3B gRNA knockout on proliferation was assessed by both (b)
MTS assay (n= 3, SEM, ***p < 0.001, statistically normalized to
nontargeting control) and (c) RTCA. (n= 3, SEM, ***p < 0.001).
d Knockdown of KDM3B caused decreased proliferation only in
androgen independent cell lines. Cellular proliferation was measured
by MTS (d) (n= 3, SEM, ***p < 0.001) and by RTCA (n= 3, SEM)
(e) after cells were transduced, selected and grown for 1 week.
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rather than an accumulation at a particular stage. We
observed no significant difference in global H3K9me2
between shFF and shKDM3B suggesting that KDM3B may
have locus specific targets in LNCaP-abl (Supplementary
Fig. S6). To explore this, we characterized the transcriptome
following KDM3B knockdown at two different time points
based on our RTCA growth experiments, one at the lag
phase (7 days post transduction) and another in the growth
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phase (14 days post transduction). At the early time point, a
total of 149 genes were significantly differentially expressed
(false discovery rate (FDR) <0.05) in LNCaP-abl cells
treated with shKDM3B as compared with shFF. At the later
time point (14 days post transduction), a total of 55 DEGs
were found to be significant in shKDM3B relative to shFF.
H3K9me3 is a critical repressive mark and is typically
found in gene-poor regions leading to permanent repression
[45]. However, in shKDM3B treated cells, the majority of
differentially expressed genes (DEGs) were found to be
upregulated, though the magnitude of the change in relative
expression level was not dramatic. In contrast, almost no
DEGs were found in shKDM3B treated LNCaP cells rela-
tive to shFF (Fig. 4c, d). Excluding KDM3B, only three
DEGs were shared between LNCaP-abl and LNCaP cells:
ZIK1, ZSCAN18, and ARL6IP1. In shKDM3B treated
LNCaP-abl cells, commonly DEGs included: KDM3B,
ABCA12, PRUNE2, MAP7D1, APOD, ARG2, FN1, S1PR3,
MYLK, CASC5, ARL6IP1, STMN1, and SDCBP2. Gene set
enrichment analysis indicated the enrichment of MYC tar-
gets in shKDM3B treated cells (Fig. 4d). In agreement with
our earlier work, we did not observe any significant changes
in AR regulated genes (Supplementary Fig. S1c). These
results were validated with qRT-PCR (Fig. 4e, Supple-
mentary Fig. S7). Of these, a number of metabolic genes
including ARG2 and RDH11 were downregulated in
shKDM3B cells (Fig. 4e). To investigate the clinical
importance of our findings, we analyzed publicly available
PCa expression data [46]. We did not detect any significant
upregulation of KDM3B expression in CRPC patients as
compared with primary PCa. Next, we compared the
expression levels of three categories of KDM3B-regulated
DEG in primary PCa versus CRPC [47] (Supplementary
Fig. S8). We found that non-KDM3B associated genes
(unchanged) were higher expressed in CRPC than primary
PCa. This well-known phenomenon is proposed to be due
to enhanced chromatin accessibility in CRPC [48, 49].
Compared with this, the DEGs impacted by KDM3B were
expressed both higher (upregulated DEGs) and lower
(downregulated DEGs) than non-KDM3B associated genes
indicating greater KDM3B activity in CRPC. Overall these
data suggest that KDM3B alters expression of both MYC
targets and metabolic genes in LNCaP-abl cells and that
these genes are elevated in late-stage PCa patients.
Given that KDM3B knockdown alters metabolic gene
expression but does not impact cell cycle, we proposed that
the decrease in proliferation could be due to reduced cellular
metabolic activity. To explore this, we examined the effect
of KDM3B knockout on the relative abundance of meta-
bolites in the cellular metabolome using untargeted liquid
chromatography–tandem mass spectrometry (LC–MS/MS).
Three separate LC–MS/MS methods were used to provide
an overview of the cellular metabolome comparing gRNA-
KDM3B1 treated cells with nontargeting gRNA treated
samples (14 days post transduction; n= 5). Over 3000
compounds features were measured with a %CV < 30 but in
general, few significant differences in metabolite feature
abundances were observed. In total 170 metabolites were
identified (matched to authentic standards, see “Materials
and methods” section) of which six metabolites were sig-
nificantly altered in abundance (fold change > 1.5, FDR
adjusted p value < 0.1) following the KDM3B knockout
(Fig. 5a) Interestingly, we observed a clear enrichment in 2-
OG levels with the loss of KDM3B (Fig. 5b). As 2-OG is a
cofactor of KDM3B and utilised during catalysis [36, 50],
this observation is in agreement with its enzymatic
mechanism. Other TCA metabolites such as citrate and
succinate, (the latter being the by-product of KDM3B cat-
alysis [36, 50]) remained largely unchanged (Fig. 5b). We
also observed a marked, though nonsignificant, decrease in
the arginase metabolite ornithine and downstream product
citrulline (Fig. 5b). There was a clear enriched of the
metabolites sedoheptulose-7-phosphate, sodeheptulose-1,7-
phosphate, and phosphoribosyl pyrophosphate. Both 2-
aminoadipate (found in the lysine degradation pathways
[51]) and histidine were reduced in the KDM3B knockout.
Discussion
Previous work has demonstrated that chromatin modifying
enzymes play an important role in the cellular differentia-
tion that occurs during CRPC progression [10, 11]. How-
ever, to date, a systematic large-scale study that
characterizes the role of many different chromatin modifiers
in CRPC is lacking. In this study, we conducted an unbiased
loss-of-function screen targeting chromatin modifiers pre-
viously shown to be involved in stem cell development. We
proposed that such enhancers or barriers of stem cell
reprograming are likely to be involved in transition or
maintenance of androgen-independent PCa [23]. Our screen
suggested that the disruption of the chromatin methylation
dramatically affects the proliferative capacity of the cells.
Fig. 3 Histone demethylase activity of KDM3B is important for
growth in LNCaP-abl cells. a Isoforms of KDM3B and cartoon
representation of overexpression constructs. b Immunofluorescence
microscopy of H3K9me2 following transfection with the over-
expression construct. DAPI was used to stain nuclei. c Genetic rescue
experiment of shRNA treated cells. Following transduction, cellular
proliferation was assayed by MTS assay after 7 days (n= 13, SEM,
***p < 0.001, statistically normalized to shKDM3B control).
d LNCaP-abl, LNCaP, and RWPE-1 cells were treated with small
molecule inhibitors JIB-04, IOX1, and DMOG for 5 days. Cell via-
bility was measured by MTS. Top: depicted pIC50 values for inhibi-
tors were calculated by following equation pIC50=−Log (IC50/M) for
each cell line. Bottom: dose-response curve for JIB-04 treatment. (n=
2, SEM).
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Overall, knock down of methylation related enzymes
appeared to enhance proliferation while loss of demethy-
lases, in particular the H3K9 demethylases KDM4s/
KDM3s, decreased growth in LNCaP-abl. Importantly, this
was not due to shRNA off-target effects as a similar phe-
notype with both different shRNA and CRISPR/Cas9 was
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observed. KDM3B was only important in AR expressing
androgen-independent CRPC cell lines but not androgen-
dependent PCa or immortalized prostate epithelial cells. Our
results suggest that KDM3B dependency is specific to a
subset of CRPC cell lines that are used to model a clinically
important patient population. As shown by experiments in
androgen supplemented media and confirmed with the gene
expression studies, the effect of KDM3B on CRPC pro-
liferation was independent of AR signaling. In rescue
experiments the phenotype was specific to the catalytic
function of KDM3B. Only wild-type KDM3B was found to
remove H3K9me2 and rescue the proliferative phenotype.
Surprisingly, expression of ΔZF KDM3B resulted in further
decreased proliferation of shKDM3B treated cells. While
speculative, this could be due to a dominant negative effect
[52]. Biochemical studies demonstrated that zinc-finger
domain and JmjC domain are required for KDM3A cata-
lytic function due to homodimer formation via these
domains [14, 53]. Overexpression of ΔZF KDM3B may
thus inactivate the endogenous KDM3B. Similar to
KDM3A, KDM3B may undergo homodimerization; how-
ever additional studies are needed.
KDM3B is an H3K9me2 demethylase that belongs to the
KDM3 family [39, 54]. Despite the contradictory results on
the function of KDM3B, demethylation of H3K9me1/2
generally correlate with active transcription [40]. KDM3B
is proposed to be a tumor suppressor gene in myeloid leu-
kemia, colorectal cancer, and breast cancer [55–59]. It also
contributes to repression of angiogenesis by downregulating
ANGPT1 [38]. In contrast, studies also showed that
KDM3B localizes to promoter region of lmo2 gene and
drives leukemogenesis [40]. A recent study demonstrated
that knockout of KDM3B in mice led to defective sper-
matogenesis and litter size [16].
Despite the clear decrease in cellular growth of LNCaP-
abl, the cell cycle distribution was not affected by KDM3B
knockdown. While uncommon, this phenotype has been
previously observed. Knockdown of 60S ribosomal proteins
in human fibroblasts has been shown to result in decreased
proliferation due to impaired ribosome biogenesis without
changes in cell cycle distribution [60]. In MCF-10A cells,
knockdown of the BRG1 or BRM1 subunit of SWI/SNF
ATPase leads to decreased proliferation and in the
absence of intact p53, cell cycle distribution remains
unaffected [61]. Although KDM3B depletion does not
cause cell death, it did significantly decrease proliferation
in androgen-independent CRPC. This does not mean
KDM3B is not clinically important. In our models of
CRPC, the loss of KDM3B had a profound decrease on
cellular proliferation.
Given the similar H3K9me2 levels detected in control
versus shKDM3B, it is very likely that KDM3B possesses
locus specific targets in androgen-independent CRPC. In
accordance with this, analysis of the global gene expression
changes by RNA-sequencing following KDM3B knock-
down showed that a relatively limited number of genes were
differentially expressed between the control and shKDM3B
samples. Moreover, the DEGs were found to be elevated in
clinical metastatic PCa [47]. The expression of AR or its
target genes were unaffected by shKDM3B treatment, thus
demonstrating that KDM3B, in contrast to other KDM
members, does not act via AR [11, 18, 37, 62]. LNCaP cells
were largely unaffected by KDM3B knockdown. However,
we observed a clear decrease of ARG2 and RDH11 in
LNCaP-abl cells. ARG2 is involved in arginase metabolism
in the cells [63] and highly expressed in healthy prostate
tissue [64, 65]. In agreement with these results we observed
a marked decrease in the arginase metabolite ornithine.
Interestingly, it has been reported that LNCaP cells cultured
in androgen depleted medium led to decrease in ARG2
levels in an IL-8 dependent manner [63]. RDH11 is
involved in the metabolism of retinoic acid and is highly
expressed in prostate epithelium [66]. When cells are treated
with all-trans retinoic acid (ATRA), RDH11 expression was
found to decrease [67]. ATRA treatment in AML also leads
to decrease in KDM3B levels as well [40]. Overall, these
data suggest likely mechanisms in which CRPC growth is
affected by KDM3B, which are independent of changes in
canonical AR pathway or cell cycle distribution.
Metabolomic profiling revealed subtle changes in
KDM3B knockout LNCaP-abl cells. The observed increase
in 2-OG on KDM3B knockout likely reflect its reduced use
as a cofactor in KDM3B catalysis [36]. However, several
amino acids including histidine, tyrosine were reduced after
KDM3B knockout. These have been demonstrated to be
important in PCa. In an unbiased metabolomic analysis
comparing blood samples from the patients with benign
prostatic hyperplasia and PCa (Gleason score > 6), elevated
levels of several metabolites including histidine, tyrosine,
and others were found in PCa [68]. In the same study, these
potential biomarkers were found to be associated with
arginine metabolism and lysine degradation [68]. However,
further investigation is required to better understand the role
of KDM3B in metabolism.
While there are no selective KDM3 inhibitors to date,
JmjC-KDM inhibitors show promise in PCa. The KDM4
inhibitor B3 demonstrate antiproliferative activity against
Fig. 4 Knockdown of KDM3B did not cause a blockade in any cell
cycle stage. a Overlay of PI staining in shFF, shKDM3B-1, and
shKDM3B-2 treated LNCaP-abl cells. b Quantification of PI staining
in the cells. KDM3B knockdown alters gene expression in LNCaP-abl.
c Heatmap of differentially expressed genes (DEGs) with false dis-
covery rate (FDR < 0.05) in LNCaP-abl. d Venn diagram of DEGs in
LNCaP-abl and LNCaP and GSEA analysis performed with DEGs in
LNCaP-abl. e Hits from DEGs with FDR < 0.05 were validated in
shKDM3B-treated LNCaP-abl using qPCR (n= 3, SEM).
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Fig. 5 Untargeted metabolomic analysis of KDM3B knockout cells.
a Volcano plot presenting all identified compound features (%CV <
30). Metabolites that were altered in the KDM3B knockout (fold
change > 1.5 and FDR adjusted p value < 0.1) are highlighted in
orange and annotated with the compound name. b Box plots showing
the significance of differences in metabolites between KDM3B
knockout (KDM3B) and nontargeting controls. (SEM, n= 5, FDR-
adjusted * p < 0.1, **p < 0.05, ***p < 0.005).
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both PCa and CRPC [69]. Pan-KDM inhibitor (targeting
both KDM1 and KDM2-7 families) inhibit LNCaP cell
proliferation, induce cell cycle arrest and apoptosis [70].
JIB-04, a pan-JmjC inhibitor that targets KDM2-7 including
KDM3 [42, 71, 72], selectively inhibits growth of cancer-
ous over normal prostate cells [41]. In this study, we have
demonstrated CRPC LNCaP-abl are more sensitive to JIB-
04 than LNCaP cells. While speculative, our results suggest
that there are alterations in KDM dependencies between
androgen-dependent and -independent PCa. Selective che-
mical tools for KDM3 subfamily, specifically for KDM3B,
are required to decipher the mechanism of action and for
target validation.
In conclusion, we have identified KDM3B to be impor-
tant for the proliferation of CRPC cells. While the
mechanism of action is complex, the requirement of the
KDM3B catalytic activity for CRPC cellular proliferation
suggests this may potentially be a novel pharmacological
target.
Materials and methods
Plasmids, viral construction
The shRNA library was described previously [23, 73].
pENTR/TEV-D-TOPO-KDM3B plasmid was kindly gifted
by Dr Catrine Johansson and Prof. Dr Udo Oppermann.
This plasmid was used for cloning of three hemagglutinin
tags to the C-terminal of KDM3B and transferred into
gateway destination vectors. Primer sequences are given in
Supplementary Table S2.
Cell culture
LNCaP, PC3, 22Rv1, and DU-145 cells were cultured in
RPMI1640 (Lonza, Switzerland) with 1% penicillin-
streptomycin (Invitrogen, Netherlands) and 10% fetal
bovine serum (FBS) (Gibco, Netherlands). LNCaP-abl
and LNAI cells were maintained in RPMI 1640 (Lonza,
Switzerland) with 1% penicillin-streptomycin (Invitro-
gen, Netherlands) and 10% charcoal stripped FBS (CSS)
(Biowest, France). RWPE-1 cells were grown in kerati-
nocyte serum-free media with required supplements
(Gibco, Netherlands). HEK293T and VCaP cells were
grown in DMEM (Lonza, Switzerland) supplemented
with 10% FBS (Invitrogen, Netherlands) and 1%
penicillin-streptomycin. All cells were grown in 37 °C
humidified incubator with 5% CO2. LNCaP-abl cells were
a generous gift from Dr Helmut Klocker. All cell lines
used in this study were validated by short-tandem repeats
profiling on July 24, 2016. Cells were routinely mon-
itored for mycoplasma.
Transfection of the cells and viral packaging
Cells were transfected according to the manufacturer’s
instructions (FuGene, Promega, USA; Lipofectamine 3000-
Thermo Fisher Scientific, USA). Viral packaging of plas-
mids was described previously [23].
Transduction and stable cell line preparation
Cells were transduced with viral particles in the presence of
8 µg/ml protamine sulfate. Two days post infection, cells
were selected with antibiotics and post selection, they were
recovered for 1 day in their culture media. Finally, stable
cells were expanded and used for further experiments.
Short hairpin RNA knockdown
To generate KDM3B knockdown, cells were transduced
with retrovirus particles containing shRNA. Knockdown
was validated by qRT-PCR and/or western blot. shRNA
sequences are given in Supplementary Table S1.
gRNA-mediated knockout of KDM3B expression
CRISPR/Cas9 system was conducted to generate KDM3B
knockout cells. Briefly, pLKO5.sgRNA.EFS.GFP plasmids
(Addgene, #57822) [74] expressing single gRNA targeting
KDM3B or AR was generated and transduced into cells
stably expressing Cas9 protein. sgRNA sequences are given
in Supplementary Table S2.
Cell proliferation and cell cycle assays
For cell proliferation, cells (2000 cells/well) were plated into
96-well plates and MTS assay was performed as per the
manufacturer’s instructions (Promega, USA). For RTCA
experiment, cells (2500 cells/well) were plated into E-plate
View (Acea Biosciences, USA) and measured every 20min.
For cell cycle analysis, shRNA treated cells (grown for
7 days) were stained with propidium iodide using a standard
protocol [75]. For BrdU staining, shRNA treated LNCaP-abl
cells (grown for 7 days) were treated with BrdU, washed,
fixed, and DNA was denatured. Then, the cells were stained
with anti-BrdU-FITC and propidium iodide and analyzed by
flow cytometer. The staining experiments were repeated
eight times, each time with knockdown validation. For
inhibitor treatment, cells were treated with inhibitor for
5 days and viability was measured by MTS assay.
Western blot
Protein lysates were extracted using lysis buffer supple-
mented with protease inhibitors, mixed with 4× Laemmli
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buffer (Bio-Rad, USA). Western blot was performed as
previously described [76]. Antibodies are shown in Sup-
plementary Table S3.
Immunofluorescence staining
Transfected HEK293T cells were fixed with 1% paraf-
ormaldehyde, permeabilized using 0.5% Triton X-100, and
blocked using 3% BSA. Primary antibodies were given
overnight at 4 °C. Cells were then washed with PBS and
incubated with secondary antibodies. Stained cells were
placed on slides with Vectashield with DAPI (Vector
Laboratories, USA) and visualized with Nikon Eclipse 90i
at ×100 magnification.
Gene expression analysis
For mRNA isolation, NucleoSpin® RNA (Macherey-Nagel,
Germany) kit was used as per the manufacturer’s instruc-
tions. cDNA was prepared busing MMLV-reverse tran-
scriptase (Thermo Fisher Scientific, USA). qRT-PCR was
performed with LightCycler® 480 SYBR Green I Master
(Roche, Switzerland). The primers used in qRT-PCR are
listed in Supplementary Table S2.
RNAseq
RNAseq experiment was performed at two different time
points (t= 7 days and t= 14 days). For both time points
RNA samples were sequenced on a HiSeq4000, the reads
were mapped on hg19 genome build by HISAT2 software.
mRNA counts were calculated using HTSeq software.
DEGs were identified using DESEQ2. Gene set enrichment
analysis was performed by using publicly available gene
sets data (http://software.broadinstitute.org/gsea/msigdb/
index.jsp) [77]. Gene Expression Omnibus accession
number for RNAseq analyses is GSE127904.
KDM3B DEG expression in CRPC patients
Based on their response to shKDM3B, DEGs were grouped
into downregulated, unchanged, and upregulated. RPKM
values for DEGs in primary and metastatic PCa samples
were obtained from cBioPortal (GSE21032) [47, 78, 79].
Wilcoxon test was used for statistical analysis.
Metabolic profiling
Metabolites from LNCaP-abl cells treated with gRNAs for
KDM3B knock out (n= 5) were extracted into ice-cold
methanol. Cells lysate was collected, centrifuged, DNA
content was measured and filtered (10 kDa MWCO). The
samples were analysed using three LC-MS methods: anion-
exchange chromatography-mass spectrometry and reversed-
phase chromatography-mass spectrometry (positive and
negative ion mode). Post-sample analysis, Progenesis QI
software, was used for raw data processing, which included
peak alignment, isotope cluster recognition, and compound
identification. Compound identification was performed by
matching compound features to four measurement para-
meters associated with authentic standards. Matches were
based on accurate mass measurement (<5 ppm), experi-
mental retention window time (<30 s), matching fragmen-
tation patterns where applicable and isotope patterns
matched with the standard (>90%). MetaboAnalyst was
used for data processing and statistical analysis. FDR
adjusted p values were used throughout for analysis of
metabolomics data (Fig. 5) to account for the size of
abundance differences in comparison to the overall variance
(i.e., the range of abundance values).
Statistical analysis
Statistical analysis is described in the figure legends where
n describes number of biological replicates. All in vitro
experiments were performed at least three independent
times (except Fig. 3d and Supplementary Fig. S4). Mean ±
S.E.M. was used for data representation. Two tailed Stu-
dent’s t test was used for the comparison of the difference
between two groups. For RNAseq, FDR < 0.05 was used as
significance cutoff. In all figures (except Fig. 5), *p < 0.05,
**p < 0.01, and ***p < 0.001 was used to demonstrate
significance.
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